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Available online 8 June 2016Amyotrophic Lateral Sclerosis (ALS) is a severe and fatal neurodegenerative disease characterized by progressive
loss of motoneurons, muscle atrophy and paralysis. Recent evidence suggests that ALS should be considered as a
multi-systemic disease, in which several cell types contribute to motoneuron degeneration. In this view, muta-
tions inALS linked genes in other neural and non-neural cell typesmay exert non-cell autonomous effects onmo-
toneuron survival and function. Induced Pluripotent Stem Cells (iPSCs) have been recently derived from several
patients with ALS mutations and it has been shown that they can generate motoneurons in vitro, providing a
valuable tool to study ALS. However, the potential of iPSCs could be further valorized by generating other cell
types that may be relevant to the pathology. In this paper, by taking advantage of a novel inducible system for
MyoD expression, we show that both control iPSCs and iPSCs carryingmutations in ALS genes can generate skel-
etal muscle cells. We provide evidence that both control andmutant iPSC-derivedmyotubes are functionally ac-
tive. This in vitro system will be instrumental to dissect the molecular and cellular pathways impairing the
complex motoneuron microenvironment in ALS.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Skeletal muscle1. Introduction
Amyotrophic Lateral Sclerosis (ALS) is a fatal disease that leads to
death due to loss ofmuscle function. A subset of ALS cases has a clear ge-
netic component and in the last years the list of genes associated with
the disease has been greatly expanded (Renton et al., 2014). Among
them, the gene encoding for the Cu/Zn superoxide dismutase 1
(SOD1) was the ﬁrst one being associated with familial ALS (fALS)
(Rosen et al., 1993). Other fALS mutations in the RNA binding proteins
Fused in Sarcoma/Translocated in Liposarcoma (FUS/TLS or FUS) and
Tar DNA Binding Protein 43 (TDP-43) suggest that RNA metabolism
may play a relevant role in ALS pathogenesis (Lagier-Tourenne et al.,
2010). Despite several pathogenic mechanisms have been proposed
for the role of mutated SOD1, FUS and TDP-43 in ALS, a clear under-
standing of themolecular and cellular pathways leading tomotoneuron
degeneration andmuscle atrophy is still missing. Thismay be partly due
to the multi-systemic nature of ALS. The non-cell-autonomous effects
on motoneurons of ALS mutations in other cell types have been quite
extensively studied for SOD1 (Musarò, 2012). SOD1 mutant).
. This is an open access article undermotoneurons mortality was reduced in chimaeric mice having WT
nonneuronal cells and, conversely, WT motoneurons surrounded by
mutant glia showed ALS hallmarks, such as ubiquitin aggregates
(Clement et al., 2003; Yamanaka et al., 2008). These in vivo studies are
also supported by analysis of co-culture in vitro systems, in which mu-
tant astrocytes increased neurodegeneration of WT motoneurons de-
rived from mouse or human pluripotent cells (Di Giorgio et al., 2007;
Nagai et al., 2007; Di Giorgio et al., 2008). Non-cell autonomous effects
of SOD1 mutations have been observed not only for astrocytes, but
also for other non-neuronal cells. For instance, expression of mutant
SOD1 in microglia affected disease progression in mice (Boillee et al.,
2006). Moreover, it has been shown that mutant SOD1 expression in
skeletal muscle led to muscle atrophy and functional impairment in a
mouse model (Dobrowolny et al., 2008).
A new twist in the study of ALS has come by the generation of
human induced Pluripotent Stem Cells (iPSCs). As iPSCs can be derived
from patients carrying ALS mutations and can differentiate into a wide
range of cell types, they represent a valuable opportunity for disease
modeling in vitro. Several groups have reported the derivation and
characterization of iPSCs derived from fALS individuals with mutations
in SOD1, TDP-43 and, more recently, FUS (Dimos et al., 2008; Boulting
et al., 2011; Bilican et al., 2012; Egawa et al., 2012; Lenzi et al., 2015).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in ALS-iPSCs differentiated to motoneurons, including delocalization of
mutant proteins (Bilican et al., 2012; Egawa et al., 2012; Lenzi et al.,
2015), neurite degeneration (Chen et al., 2014), electrophysiological de-
fects (Wainger et al., 2014), increased oxidative stress (Kiskinis et al.,
2014) and vulnerability (Bilican et al., 2012; Egawa et al., 2012;
Kiskinis et al., 2014). These reports provide the proof of principle that
iPSCs can be used to model ALS disease in vitro. iPSCs are pluripotent
and can generate multiple cell types, provided that appropriate differ-
entiation protocols are used. In this work, we designed and optimized
a protocol for muscle differentiation from iPSCs. As previously shown,
human pluripotent cells can be converted intomuscle by the ectopic ex-
pression of myogenic factors (Darabi and Perlingeiro, 2014; Tedesco et
al., 2012; Tanaka et al., 2013; Abujarour et al., 2014). Our strategy is
based on the inducible expression of themaster geneMyoD from an in-
tegrative vector, derived from the enhanced piggyBac transposon
(Lacoste et al., 2009). We show that control and ALS iPSC lines can
give rise to mature myotubes endowed with functional properties. A
convenient feature of our protocol is the possibility to produce stable
cell lines that can be induced to muscle differentiation by doxycycline
treatment.
2. Materials and methods
2.1. Generation and maintenance of human iPSCs
The iPSC lines were generated and validated as described in Lenzi et
al. (2015). All iPSC lines were maintained in Nutristem-XF (Biological
Industries) in plates coated with hESC-qualiﬁed Matrigel (Corning)
and passaged every 4–5 days with 1 mg/ml Dispase (Gibco). Clones
used in the experiments shown were: WT I clone#1; ALS I (FUSR514S/
WT) clone#1; ALS II (FUSR521C/WT) clone#34 and ALS III (TDP-43A382T/
A382T) clone#2.
2.2. Plasmid construction and generation of stable iPSCs lines
The epB-Puro-TT-mMyoD plasmid was generated by inserting the
coding sequence of mouse MyoD (GenBank: M84918.1) in the en-
hanced piggyBac transposable vector epB-Puro-TT (Rosa et al., 2014).
The resulting construct contains the piggyBac terminal repeats ﬂanking
a constitutive cassette driving the expression of the Puromycin resis-
tance gene fused to the rtTA gene and, in the opposite direction, a tetra-
cycline-responsive promoter element (TRE) driving the expression of
MyoD. iPSCs were co-transfected with 4 μg epB-Puro-TT-mMyoD and
1 μg of the piggyBac transposase using the Neon Transfection System
(Life Technologies) as previously described (Lenzi et al., 2015). Selec-
tion in 0.5 μg/ml puromycin gave rise to stable and inducible cell lines.
2.3. Differentiation of iPSCs into muscle cells
iPSCs were passaged (passage number around 10 to 20) in 35 mm
dishes. For differentiation as colonies (Fig. 1A, Colonies), the medium
was replaced with HUESM (DMEM-F12+Glutamax, Life Technologies;
20% Knockout Serum Replacement, Life Technologies; 1X Non-Essential
Aminoacids, NEAA, Life Technologies; 100 U/ml Penicillin +100 μg/ml
Streptomycin, Sigma; 0,1 mM β-mercaptoethanol, Gibco). This is con-
sidered day 0 (D0). At day 6 themediumwas replacedwith GrowthMe-
dium (GM; DMEM High Glucose Medium, Sigma; 20% FBS, Sigma;
25 ng/ml bFGF, Corning; 10 ng/ml EGF, Corning; 50 μg/ml Insulin,
Roche; 2 mM L-Glutamine, Sigma; 100 U/ml Penicillin +100 μg/ml
Streptomycin, Sigma) in presence of 200 ng/ml doxycycline (Sigma).
At day 8 the medium was replaced with Differentiation Medium (Skel-
etal Muscle Cell DifferentiationMedium, Promocell; 100 U/ml Penicillin
+100 μg/ml Streptomycin, Sigma) in presence of 200 ng/ml doxycy-
cline. For differentiation as single cells (Fig. 1A, Single cells), iPSCs colo-
nies were dissociated as single cells with Trypsin-EDTA 1X (EuroClone)and 150,000 cells seeded on 35 mm dishes in Nutristem-XF supple-
mentedwith 10 μMRock inhibitor (Y-27632, Sigma) to enhance surviv-
al upon dissociation. The next day, the medium was replaced with
HUESM (D0). At day 5 themediumwas replaced with GM supplement-
edwith 200 ng/ml doxycycline. At day 7 themediumwas replacedwith
DM supplemented with 200 ng/ml doxycycline. For the experiments
shown in Fig. 2, the outline is depicted in Fig. 2A. Differentiation started
from60,000 cells seeded as single cells in eachwell of a 12-well plate for
condition A and 1–5 and from40,000 cells in eachwell of a 12-well plate
for condition B. For the experiments shown in Fig. 4, 60,000 cells, disso-
ciated as single cells, were seeded in 35 mm dishes and maintained in
Nutristem-XF supplemented with 10 μM Rock inhibitor for 2 days, be-
fore the switch to HUESM (D0).
2.4. RT-PCR and real-time qRT-PCR
Total RNAwas extracted with the RNeasy kit (Qiagen). For real-time
qRT-PCR and RT-PCR RNA was retrotranscribed with the SuperScriptIII
kit (Invitrogen). As negative controls, minus-reverse transcriptase sam-
ples have been included in subsequent ampliﬁcation reactions (not
shown). For RT-PCR, cDNA was used as template with the BioTaq DNA
polymerase (Bioline). Real-time qRT–PCR analysis was performed
with SYBR Green QPCR Master Mix (Qiagen) in a 7500 Fast Real Time
PCR System (Life Technologies) and calculations performed with the
delta delta Ct method. The internal control is the housekeeping gene
ATP5O (ATP synthase, H+ transporting, mitochondrial F1 complex, O
subunit) in real-time qRT–PCR analyses and GAPDH for RT-PCR. Primers
sequences are reported in Supplemental Table 1.
2.5. Immunostaining
Cells were ﬁxed in 4% paraformaldehyde for 20min at room temper-
ature and washed twice with PBS. Fixed cells were then permeabilized
with PBS containing 1% BSA and 0.2% Triton X-100 and incubated with
primary antibodies: monoclonal mouse anti-MyoD1, clone 5.8 A (1:50,
4 °C overnight, DAKO M351201), anti-Myosin Heavy Chain (myosin II)
monoclonalmouse IgG2B fromhybridomaculture (Clone#MF20)undi-
luted supernatant (room temperature, 1 h), anti-MyoG monoclonal
mouse from hybridoma culture (Clone #F5D) undiluted supernatant
(room temperature, 1 h). The secondary antibodies used are: GOAT
anti-mouse Alexa Fluor 488 (1:300, room temperature 1 h, Invitrogen),
GOAT anti-mouse Cy3 (1:600, room temperature 1 h, Jackson
ImmunoResearch). DAPI (Sigma-Aldrich) was used to label nuclei.
Cells were imaged with an Axioscope (Zeiss) microscope. For quantita-
tive analysis, cells were imaged with an inverted Olympus iX73 micro-
scope equipped with an X-light Nipkow spinning-disk head (Crest
Optics) and Lumencor Spectra X LED illumination; images were collect-
ed using a CoolSNAP MYO CCD camera (Photometrics) and analyzed
with ImageJ.
2.6. Patch-clamp recordings
Patch-clamp recordings were obtained using glass electrodes (3–
5 M Ω) ﬁlled with the following intracellular solution (in mM): 140
KCl, 2 MgCl2, 10 HEPES, 2 MgATP, 5 BAPTA; pH 7.3, with KOH. During
experiments, cells were continuously superfused with a normal extra-
cellular solution (NES) containing (in mM): 140 NaCl, 2.5 KCl, 2 CaCl2,
2 MgCl2, 10 HEPES-NaOH and 10 glucose (pH 7.3), using a gravity-driv-
en perfusion system connected to a VC-6 valve controller (Warner In-
struments). All recordings were performed at 24–25 °C. ACh-evoked
currents, recorded with a patch-clamp ampliﬁer (Axopatch 200B; Mo-
lecular Devices, Foster city, CA, USA), were ﬁltered at 1 kHz, digitized
(10 kHz) and acquired with Clampex 10 software (Molecular Devices).
Cells were voltage-clamped at a holding potential of −70 mV. ACh
dose–response were studied applying to each cell three different
doses of the transmitter (3, 30, 300 μM) for 1 s. ACh-evoked currents
Fig. 1. InducibleMyoD expression vector andmuscle differentiation protocol. (A) Top: schematic representation of the epB-Puro-TT-mMyoD construct. pA: polyadenylation signal; PuroR:
puromycin resistance gene; T2A: self-cleavage peptide; rtTA: TET transactivator protein gene; Pubc: human Ubiquitin C constitutive promoter; TRE: TET responsive element; Dox:
doxycycline. Blue triangles represent terminal repeats of the transposon. Bottom: diagrams of the differentiation protocols, starting from iPSC colonies (Colonies) or dissociated as
single cells (Single cells). HUESM: iPSC differentiation medium; GM: myoblast growth medium; DM: myoblast differentiation medium. Red line: time in doxycycline (Dox). Time
points of medium change are indicated above. (B) Bright ﬁeld imaging of differentiated WT I-MyoD cells. “Single cells (no Dox)” indicate a control differentiation in which doxycycline
had been omitted. (C) Immunostaining for the muscle markers (red): MYOD (left panels), Myogenin (middle panels) or Myosin Heavy Chain (MYH1; right panels), in WT I-MyoD
cells differentiated as shown in panel (A). Nuclei are counterstained with DAPI. Scale bar for all panels: 50 μm. The percentages of positive cells were: 94.5% (Colonies; n = 1039
nuclei) versus 90.8% (Single Cells; n = 185 nuclei) for MYOD; 38.6% (Colonies; n = 690 nuclei) versus 16.1% (Single Cells; n = 31 nuclei) for Myogenin; 37.7% (Colonies; n = 2915
nuclei) versus 67.5% (Single Cells; n = 3905 nuclei) for MYH1.
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Bungarotoxin-ATTO-488, Alomone Labs) for 2 h. Data were analyzed
off line with Clampﬁt 10 sofware; Origin 7 software was used for statis-
tical analysis of electrophysiological data.
2.7. Intracellular calcium measurements
Fluorescence determinations were performed by using a conven-
tional ﬂuorescence microscopy system composed of an upright micro-
scope (Axioscope 1, Zeiss), a digital 12-bit cooled camera (SensiCam),
and a monochromator (Till Photonics). The system was driven by
Metaﬂuor (Molecular Devices). Images were acquired and stored on a
HP PC, then analyzed ofﬂine. Before the experiments, cells were incu-
bated with Fura-2 AM (3 μM) for 45 min and then extensively washed
with NES. To measure Fura2 ﬂuorescence, cells were visualized with a
40× objective and illuminated with a Till 2 monocromator at 340 nm
and 380 nm excitation wavelengths. Fluorescent images were recorded
every 500 ms with a Photometrics (coolsnap ez) camera. Images were
binned 2 × 2 recorded and background-subtracted ratio images pro-
duced using Metaﬂuor software (Molecular Dynamics). Changes in in-
tracellular calcium were determined from the changes of ﬂuorescence
ratio (F340/F380).3. Results
3.1. Inducible MyoD expression by enhanced piggyBac converted iPSCs into
muscle
The piggyBac vector is a transposable element that, in presence of
the piggyBac transposase, can mediate the integration of exogenous
DNA sequences into the genome of pluripotent cells. It has been previ-
ously shown that inducible expression of a MyoD transgene carried by
a piggyBac vector could induce iPSC muscle differentiation (Tanaka et
al., 2013; Shoji et al., 2016). The enhanced version of piggyBac (epB)
carries an engineered terminal repeat, which increases transposition ef-
ﬁciency in human pluripotent stem cells (Lacoste et al., 2009; Rosa and
Brivanlou, 2011; Rosa et al., 2014). We generated an epB construct con-
taining the mouse MyoD coding sequence under the control of a doxy-
cycline-inducible promoter (epB-Puro-TT-mMyoD; Fig. 1A). This vector
also contains the TET transactivator (rtTA) and a puromycin resistance
gene under a ubiquitous promoter. We co-transfected the epB-Puro-
TT-mMyoD vector with the piggyBac transposase, expressed in trans
from an independent plasmid, into iPSCs derived from a healthy donor
(WT I; Lenzi et al., 2015). Upon puromycin selection we obtained a sta-
ble cell line (WT I-MyoD). When we inducedMyoD expression in iPSCs
Fig. 2. Optimization of the differentiation protocol. (A) Diagrams of the variants of the differentiation protocol of WT I-MyoD cells. HUESM: iPSC differentiation medium; GM: myoblast
growth medium; DM: myoblast differentiation medium. Red line: time in doxycycline (Dox). Time points of medium change are indicated above. See text for details. (B) Real-time
qRT-PCR analysis of Myogenin (white bars) or Myosin Heavy Chain (MYH1; black bars) in cells differentiated as depicted in panel (A). Relative levels of mRNA were calculated with
the delta delta Ct method and condition A is used as the calibrator sample. Error bars: standard error from a triplicate. (C–D) Immunostaining for the muscle marker MYH1 in WT I-
MyoD cells differentiated with protocol A (panel C) or 5 (panel D). Nuclei are counterstained with DAPI. Scale bar for both panels: 50 μm. (E) RT-PCR analysis of muscle markers in WT
I-MyoD cells differentiated with protocol 5 in absence (−Dox) or presence (+Dox) of doxycycline. GAPDH is used as a housekeeping control. (F-G) Real-time qRT-PCR analysis of the
indicated markers in a time-course experiment using protocol 5 (panel F) and in differentiated iPSCs (protocol 5, day 11) compared with differentiated human myoblasts (panel G).
Relative levels of mRNA were calculated with the delta delta Ct method. In panel F, for each marker the condition with higher expression has been used as the calibrator sample. In
panel G, differentiated myoblasts represent the calibrator sample. Error bars: standard error from a triplicate.
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absence of myogenic differentiation (data not shown). This is in line
with a recent report, showing that the absence of the epigenetic factor
BAF60c in undifferentiated human pluripotent cells confers resistance
to MyoD-mediated activation of skeletal myogenesis (Albini et al.,
2013; Fig. S1). We bypassed this constrain by inducingmultilineage dif-
ferentiation before doxycycline treatment. WT I-MyoD cells were cul-
tured in differentiation medium (HUESM) for six days, then switched
to myoblast growth medium (GM) in presence of doxycycline for two
days and ﬁnally cultured in myoblast differentiation medium (DM) for
additional ﬁve days (Fig. 1A, Colonies). Themorphology of the iPSCs be-
come similar to myotube-like cells (Fig. 1B) and immunostaining anal-
ysis showed expression of MYOD, Myogenin (early muscle
differentiation marker) and Myosin Heavy Chain (MYH1, late muscle
differentiation marker) in some cells (Fig. 1C). At the end of differentia-
tion, however, many cells were still negative for MYH1. To improve the
efﬁciency and reproducibility of differentiation, we dissociated WT I-
MyoD to single cells before differentiation (Fig. 1A, Single Cells). This
step improved the morphology of differentiated cells and increasedthe number ofMYH1positivemyotubes (Fig. 1B, C and S1; see Fig. 1 leg-
end for quantiﬁcation of positive cells).
3.2. Optimization of the differentiation protocol
With the aim to further improve the efﬁciency of iPSCs muscle dif-
ferentiation,we repeatedMyoD induction inWT I-MyoD cells under dif-
ferent conditions. A schematic representation of seven alternative
protocols is shown in Fig. 2A. Protocol A corresponds to the “Single
Cells” protocol of Fig. 1. In protocol B we started from fewer cells at
day 0 (see Materials and Methods). Protocols 1–5 differ for the time of
doxycycline induction and medium switch. We collected the cells at
day 12 and analyzed the expression of early (Myogenin) and late
(MYH1)musclemarkers by real-time quantitative PCR (Fig. 2B).We ob-
served that anticipating the switch to GM and/or doxycycline exposure
resulted to an increase of MYH1mRNA levels (protocols 3, 4 and 5).We
conﬁrmed this hypothesis by analyzing MYH1 protein levels by immu-
nostaining (Fig. 2C and D). Compared to protocol A, protocol 5 led to an
increase of the fraction of MYH1-positive cells (67.5% to 77.1%) and a
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1.23; n = 3905 nuclei, SD = 0.094, for condition A; n = 1995 nuclei,
SD = 0.073, for condition 5; p = 0.03, t-test).
We further characterized cells differentiated with protocol 5 for the
expression of other myogenic markers, such as DYSTROPHIN (DMD),
MEF2C and endogenous MYOD detected with human-speciﬁc primers
(Fig. 2E). A time course analysis during differentiation suggested that
the expression of muscle genes might result from gradual physiological
myogenic maturation. As shown in Fig. 2F, a peak of the expression of
themesodermmarker Brachyury (T) at day 5 is followed by amaximum
of endogenous MYOD expression at day 8. Late markers Myogenin,
MYH1 and DMD could be detected at day 8 and further increase at
day 11,whileMYOD levels decrease. Finally, we comparatively analyzed
the expression of myogenic markers in differentiated iPSCs and in dif-
ferentiated human myoblasts. Human myoblasts displayed higher
levels of MYOD andMYH1, whileMyogenin and DMDweremore abun-
dant in iPSC-derived muscle cells (Fig. 2G).
Taken together, these results suggested that bymodifying differenti-
ation conditions we improved the conversion of iPSCs into muscle cells,
which acquire the expression of relevant markers at levels comparable
to differentiated human myoblasts and in a fashion that resembles
physiological myogenic maturation.
3.3. Functional analysis of WT I-MyoD iPSC-derived skeletal muscle cells
To assess the functional differentiation of WT I-MyoD cells, we ﬁrst
analyzed their passive electrical properties, speciﬁcally the membrane
capacitance, which provides a measure of the cell surface, and the rest-
ingmembrane potential. After 12 days of differentiation, membrane ca-
pacitance of WT I-MyoD cells was 35.0 ± 5.5 pF (n = 17) and their
resting membrane potential was −31.7 ± 4.4 mV (n = 16), a value
similar to the one previously reported for fusion competent myoblasts
and mononucleate C2C12 cells (Grassi et al., 2004).
Patch-clamp recordings of differentiatedWT I-MyoD cells showed the
functional expression of nicotinic acetylcholine (ACh) receptors. Indeed
the acute application of ACh (30 μM, 1 s) always induced inward current
responses rangingbetween−0.4and−3nA(meanamplitude=−1.3±
0.2 nA; ACh 30 μM;n=11;HP=−70mV). ACh induced currents clear-
ly showed dose dependence in a range of ACh concentrations (3, 30,
300 μM; p b 0.05, One Way ANOVA; Fig. 3A). ACh induced currents
were due to the activation of nicotinic receptors, as the treatment with
α-bungarotoxin completely abolished the currents (not shown).
To further assess the functional differentiation of iPSC-derivedmus-
cle cells, we performed [Ca2+]i imaging experiments by loading cells
with Fura2 AM, a membrane-permeant and ratiometric Ca2+-sensitive
dye. In these cells, the application of ACh (3, 30, 300 μM; 1 s) inducedFig. 3. Functional properties ofWT iPSC-derived skeletalmuscle cells. (A) Left panel: dose-respo
iPSCswith the protocol 5 described in Fig. 2 (*, p b 0.05, OneWay ANOVA). Right panel: sample
(B) Average ﬂuorescence response to ACh (300 μM), in Fura-2-loaded skeletal muscle cell diffea sustained rapid and reversible increase of intracellular calcium (n =
22 cells; Fig. 3B), indicating that ACh receptors (AChRs) activation
allowed calcium inﬂux into the cells. These results suggest that differen-
tiated WT I-MyoD cells expressed functional AChRs and that their acti-
vation led to intracellular calcium elevation, which is necessary for
muscle contraction.
3.4. ALS-iPSCs can be differentiated into functionally mature myotubes
Several patient-derived ALS iPSC lines are available in our lab (Lenzi
et al., 2015). We cotransfected epB-Puro-TT-mMyoD and the piggyBac
transposase in these cells generating three additional MyoD inducible
lines: iPSC-FUSR514S/WT-MyoD, iPSC-FUSR521C/WT-MyoD and iPSC-TDP-
43A382T/A382T-MyoD. We then induced muscle differentiation in these
cells in parallel with WT I-MyoD iPSCs using an optimized protocol
(depicted in Fig. 4A), based on previous results. First, we anticipated
the GM switch and the addition of doxycycline to day 4. Second, as we
noticed different doubling times of differentiating cells in GM in biolog-
ical replicates (data not shown), we decided to keep cells in GM for only
one day to increase the reproducibility. Finally, as differentiating cells
expressed endogenous MYOD (Fig. 2E–G), and endogenous MYOD is
expected to decrease at the end of differentiation, we removed doxycy-
cline in the last 3 days to allow amore physiological maturation ofmus-
cle cells. Analysis of muscle markers by immunostaining showed that
under these conditions both normal and ALS mutant lines could be dif-
ferentiated with comparable efﬁciency (Fig. 4B and C).
Passive electrical properties of mutant cells were similar to that
measured in WT I-MyoD cells, in terms of membrane capacitance
(iPSC-FUSR514S/WT-MyoD: 49.2 ± 9.6 pF, n = 8; iPSC-TDP-43A382T/
A382T-MyoD: 48.8 ± 9.7 pF, n = 12; p = 0.2 vs WT I-MyoD, t-test) and
resting membrane potential (iPSC-FUSR514S/WT-MyoD: −34.8 ±
4.4 mV, n = 7; iPSC-TDP-43A382T/A382T-MyoD: −34.8 ± 4.4 mV, n =
9; p=0.8 vsWT I-MyoD, t-test). Patch clamp recordings of ACh-evoked
currents in ALS iPSC-derived skeletal muscle cells revealed that re-
sponses evoked by ACh in iPSC-FUSR514S/WT-MyoD were similar to
those recorded in WT I-MyoD cells (0.74 ± 0.27 nA, n = 7, ACh
30 μM, p = 0.1, t-test) (Fig. 5A). In the same analysis, however, the
iPSC-FUSR521C/WT-MyoD mutant did not show responses to ACh (data
not shown). In the case of the iPSC-TDP-43A382T/A382T-MyoD mutant,
differentiated cells displayed signiﬁcantly smaller currents compared
to WT and FUSR514S/WT cells (0.38 ± 0.21 pA, n = 9, ACh 30 μM,
p b 0.05 vs WT I-MyoD, t-test) (Fig. 5A).
Fluorescence determination in Fura2 AM-loaded cells showed that
ACh application induced transient intracellular calcium rise in FUSR514S/
WT and TDP-43A382T/A382T ALS mutant cells (Fig. 5B). Notably, ACh-in-
duced currents responses were dose-dependent in iPSC-FUSR514S/WT-nse relation of ACh-evoked currents in skeletalmuscle cells differentiated fromWT I-MyoD
traces of the three concentrations of ACh applied to aWT iPSC-derived skeletal muscle cell.
rentiated fromWT iPSC with the protocol 5 described in Fig. 2 (n = 22).
Fig. 4.Muscle differentiation of ALS-iPSC-MyoD lines. (A) Diagram of the differentiation protocol. HUESM: iPSC differentiation medium; GM: myoblast growth medium; DM: myoblast
differentiation medium. Red line: time in doxycycline (Dox). Time points of medium change are indicated above. (B) Immunostaining for the muscle markers (green): MYOD (left
panels), Myogenin (middle panels) or MYH1 (right panels), in differentiated WT I-MyoD cells or in iPSC-FUSR514S/WT-MyoD, iPSC-FUSR521C/WT-MyoD and iPSC-TDP-43A382T/A382T-MyoD
differentiated ALS mutant cells. Nuclei are counterstained with DAPI. Scale bar for all panels: 50 μm. (C) Quantiﬁcation of the fraction of MYH1-positive cells in control and ALS
differentiated cells. Histogram bars represent averages ± S.E.M. (30 ﬁelds and at least 1000 nuclei counted per line) and n.s. indicates that the differences between mutant lines and
the WT I control are not statistically signiﬁcant (p N 0.1; Student's t-test).
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cantly smaller currents without dose-dependence (Fig. 5A).
Taken together these results demonstrate that the MyoD inducible
system and differentiation protocol described here allowed the conver-
sion of multiple iPSC lines, including cells carrying ALS mutations, into
functionally active myotubes.
4. Discussion
The French neurologist Jean-Martin Charcot in 1874 was the ﬁrst to
describe anatomical lesions in the lateral spinal cord of ALS patients,thus pointing to motoneurons as the cell type primarily affected in the
disease. Since then, other neural and non-neural cell types have been
shown to contribute to this complex disease.
Both animal models and in vitro cell systems can contribute to the
dissection of molecular pathways and cellular phenotypes underlying
ALS. The SOD1 mouse model has been extensively used to study the
non-cell autonomous effects of the mutations in different cell types.
Muscle-restricted expression of mutant SOD1 elicited in this district
toxic effects, due to increased oxidative stress, associated to signs of
ALS and motoneuron degeneration in old mice (Dobrowolny et al.,
2008; Wong and Martin, 2010). However, reduction of mutant SOD1
Fig. 5. Functional properties of ALS iPSC-derived skeletal muscle cells. (A) Dose-response relation of ACh-evoked currents in skeletal muscle cells differentiated as described in Fig. 4 from
FUSR514S/WT-MyoD (light gray bars, n=7; §, p b 0.05 vs 3 μM; §§, p b 0.05 vs 3 μMand 30 μM;OneWayANOVA) and from TDP-43A382T/A382T-MyoD (dark gray bars, n=9; *, p b 0.05 vsWT
I-MyoD cells, TwoWay ANOVA) iPSCs, compared to those recorded in WT I cells (white bars, n = 11; #, p b 0.05 vs 3 μM; #, p b 0.05 vs 3 μM and 30 μM; OneWay ANOVA). (B) Average
ﬂuorescence response to ACh (300 μM) in Fura-2-loaded iPSC-FUSR514S/WT-MyoD (light gray trace; n = 18 cells) and iPSC-TDP-43A382T/A382T-MyoD (dark gray trace; n = 13 cells) cells.
146 J. Lenzi et al. / Stem Cell Research 17 (2016) 140–147in muscles did not affect disease onset or survival of transgenic mice
(Miller et al., 2006). A better understanding of the role of muscle is cru-
cial to design effective therapeutic strategies for thismulti-systemic dis-
ease. The genetic etiology of ALS also contributes to its complexity.
Despite the list of genes underlying inherited ALS has been greatly ex-
panded in the last decade, effects of non-SOD1 mutations in muscle
cells, and their possible contribution to ALS onset or progression, have
not been elucidated. In a recent report, Wachter et al. suggested that
overexpression of FUS and TDP-43 in muscle cells affects motoneuron
neurite length in an in vitro murine co-culture system (Wächter et al.,
2015). This study relied on the ectopic expression of human mutant
proteins in a mouse system. So far, a proper human model system in
which these evidences could be conﬁrmed and implemented is still
missing. In this paper we show that both normal and ALS patient-de-
rived human iPSCs can be converted to functionally mature myotubes
in vitro. One important point of strength of our system is the expression
of physiological levels of mutant proteins by human iPSC-derived cells
(Lenzi et al., 2015). Notably, ectopic expression of human WT FUS in
murine systems (in vivo or in vitro) produced the same detrimental ef-
fects observedwhenmutant proteins are used (McGoldrick et al., 2013;
Mitchell et al., 2013; Wächter et al., 2015). Such dose-dependent toxic-
ity should be taken into considerationwhen analyzing the results of ex-
periments relying on transfection of exogenous ALS-related genes.
Human iPSCs and their differentiated derivatives, such as those de-
scribed here, are not ﬂawed by this concern.
Our approach is based on the ectopic expression of the myogenic
factor MyoD in an inducible way, in cells that had stably integrated
the transgene. Transduced iPSCs represent a stable and expandable
population, in which doxycycline treatment and medium switch are
sufﬁcient to induce myogenic differentiation in few days. Even if we
do not provide comparative analysis, a survey in the literature suggests
similar timing and efﬁciency of differentiation with our system com-
pared to analogous methods (Tanaka et al., 2013; Shoji et al., 2016).
In our previous work, we have reported comparable efﬁciency of
motoneuron differentiation between WT and FUS or TDP-43 mutant
iPSCs (Lenzi et al., 2015). Herewe have extended this analysis tomuscle
differentiation showing that ALS mutations did not impair myogenesis,
as assessed by muscle markers expression. Functionally, both control
and ALS mutant iPSC-derived muscles expressed AChRs and responded
to ACh application with transient intracellular calcium increase, sug-
gesting that these cells could have reached a mature phenotype. Inter-
estingly, we detected signiﬁcantly smaller currents in the TDP-43
mutant compared to the control. Moreover, one of the FUS mutants
did not respond to ACh. Despite the fact that the fraction of cellsexpressing the muscle marker MYH1 was not signiﬁcantly different
among the lines, we cannot exclude that these differences were due to
suboptimal maturation. It should be also taken into consideration that
iPSC lines used in the present work were derived by somatic cell
reprogramming and therefore are not isogenic. In order to ascribe any
functional impairment to the genetic defect it would be necessary, in
the future, to extend this analysis to other mutants and/or compare
cell lines that differ only with respect to disease mutations, i.e. other-
wise isogenic, generated by gene editing.
The ALS-MyoD iPSC lines described here can be used to reproduce in
vitro the neuromuscular microenvironment affected by the pathology.
Despite no data on motoneuron-muscle interactions are presented
here, ALS-mutant iPSCs will allow, in the future, to establish this kind
of co-cultures. Such system would be instrumental to understand
whether FUS or TDP-43mutantmuscles can affect survival ofWTmoto-
neurons, or worsen the vulnerability of mutantmotoneurons in human.
So far, ALS phenotypes in human motoneurons have been only studied
in cultures containing neural cells (i.e. motoneurons and glia, at the
best). On the contrary, iPSC-derived motoneuron-muscle-glia co-cul-
tures may provide, in the long term, a tool to screen for therapeutic
compounds that target muscle-motoneuron interactions in ALS.Funding
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